

# Sandra Ciesek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3258735/publications.pdf>

Version: 2024-02-01

160  
papers

9,256  
citations

57758

44  
h-index

54911

84  
g-index

202  
all docs

202  
docs citations

202  
times ranked

17898  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. <i>Nature</i> , 2020, 583, 469-472.	27.8	841
2	Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. <i>Nature</i> , 2020, 587, 657-662.	27.8	818
3	Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. <i>New England Journal of Medicine</i> , 2020, 382, 1278-1280.	27.0	514
4	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 295-308.	16.8	345
5	Detection of SARS-CoV-2 in raw and treated wastewater in Germany – Suitability for COVID-19 surveillance and potential transmission risks. <i>Science of the Total Environment</i> , 2021, 751, 141750.	8.0	300
6	Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. <i>Immunity</i> , 2020, 53, 442-455.e4.	14.3	281
7	The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. <i>Hepatology</i> , 2011, 54, 1947-1955.	7.3	255
8	Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes. <i>Journal of Virology</i> , 2010, 84, 5751-5763.	3.4	201
9	Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication. <i>Molecular Cell</i> , 2020, 80, 164-174.e4.	9.7	199
10	SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. <i>Cardiovascular Research</i> , 2020, 116, 2207-2215.	3.8	189
11	Interferon- $\gamma$ -Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 1885-1897.e10.	1.3	177
12	Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. <i>Journal of Clinical Virology</i> , 2020, 129, 104480.	3.1	173
13	The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2123-2131.	3.0	159
14	The Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro. <i>Journal of Clinical Medicine</i> , 2021, 10, 328.	2.4	141
15	Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. <i>EBioMedicine</i> , 2022, 82, 104158.	6.1	128
16	Clinical performance of different SARS-CoV-2 IgG antibody tests. <i>Journal of Medical Virology</i> , 2020, 92, 2243-2247.	5.0	119
17	Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. <i>Hepatology</i> , 2009, 50, 1638-1645.	7.3	108
18	Lack of antiviral activity of darunavir against SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2020, 97, 7-10.	3.3	108

#	ARTICLE	IF	CITATIONS
19	Evaluation of a SARS-CoV-2 rapid antigen test: Potential to help reduce community spread?. Journal of Clinical Virology, 2021, 135, 104713.	3.1	102
20	An action plan for pan-European defence against new SARS-CoV-2 variants. Lancet, The, 2021, 397, 469-470.	13.7	101
21	Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scandinavian Journal of Gastroenterology, 2011, 46, 1092-1098.	1.5	94
22	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. Journal of Hepatology, 2019, 70, e81.	3.7	93
23	Inactivation and Survival of Hepatitis C Virus on Inanimate Surfaces. Journal of Infectious Diseases, 2011, 204, 1830-1838.	4.0	90
24	Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Research, 2022, 32, 319-321.	12.0	89
25	Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. Journal of Clinical Virology, 2009, 46, 210-215.	3.1	83
26	<scp>SARSâ€CoV</scp>â€2 asymptomatic and symptomatic patients and risk for transfusion transmission. Transfusion, 2020, 60, 1119-1122.	1.6	83
27	How Stable Is the Hepatitis C Virus (HCV)? Environmental Stability of HCV and Its Susceptibility to Chemical Biocides. Journal of Infectious Diseases, 2010, 201, 1859-1866.	4.0	72
28	Aprotinin Inhibits SARS-CoV-2 Replication. Cells, 2020, 9, 2377.	4.1	72
29	Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. Lancet, The, 2021, 397, 92-93.	13.7	71
30	Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q. Viruses, 2021, 13, 1693.	3.3	69
31	Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. Gastroenterology, 2010, 138, 1875-1884.	1.3	68
32	Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs. International Journal of Molecular Sciences, 2020, 21, 4396.	4.1	68
33	Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 56-61.	4.0	65
34	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection. Scientific Data, 2021, 8, 70.	5.3	65
35	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. Journal of Hepatology, 2019, 71, 301-312.	3.7	62
36	Influenza virus infection as precipitating event of acute-on-chronic liver failure. Journal of Hepatology, 2019, 70, 797-799.	3.7	62

#	ARTICLE	IF	CITATIONS
37	Multicentre comparison of quantitative PCR-based assays to detect SARS-CoV-2, Germany, March 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	60
38	The dawn of a new era in HCV therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 69-71.	17.8	57
39	Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment. <i>Journal of Infectious Diseases</i> , 2013, 207, 281-287.	4.0	57
40	Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. <i>Journal of Infectious Diseases</i> , 2021, 224, 1109-1114.	4.0	56
41	Assessment of SARS-CoV-2 Transmission on an International Flight and Among a Tourist Group. <i>JAMA Network Open</i> , 2020, 3, e2018044.	5.9	55
42	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2020, 73, S52-S53.	3.7	54
43	Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. <i>Journal of Clinical Medicine</i> , 2021, 10, 2128.	2.4	51
44	Inactivation of Hepatitis C Virus Infectivity by Human Breast Milk. <i>Journal of Infectious Diseases</i> , 2013, 208, 1943-1952.	4.0	47
45	Host cell mTORC1 is required for HCV RNA replication. <i>Gut</i> , 2016, 65, 2017-2028.	12.1	47
46	Immunosuppression, liver injury and post-transplant HCV recurrence. <i>Journal of Viral Hepatitis</i> , 2012, 19, 1-8.	2.0	44
47	Ad hoc laboratory-based surveillance of SARS-CoV-2 by real-time RT-PCR using minipools of RNA prepared from routine respiratory samples. <i>Journal of Clinical Virology</i> , 2020, 127, 104381.	3.1	43
48	Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. <i>Journal of Biological Chemistry</i> , 2021, 297, 100925.	3.4	43
49	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 326-332.	1.7	42
50	Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles. <i>Journal of Virology</i> , 2011, 85, 7613-7621.	3.4	40
51	Interferon Î± Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , 2012, 205, 1351-1362.	4.0	38
52	Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings. <i>Medical Microbiology and Immunology</i> , 2021, 210, 235-244.	4.8	37
53	Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells. <i>Stem Cell Reports</i> , 2021, 16, 419-427.	4.8	34
54	Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication. <i>Current Opinion in Virology</i> , 2015, 14, 56-61.	5.4	33

#	ARTICLE	IF	CITATIONS
55	Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants. <i>Basic Research in Cardiology</i> , 2021, 116, 42.	5.9	33
56	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	3.3	33
57	COVID-19-Related Coagulopathy—Is Transferrin a Missing Link?. <i>Diagnostics</i> , 2020, 10, 539.	2.6	32
58	Infectivity of deceased COVID-19 patients. <i>International Journal of Legal Medicine</i> , 2021, 135, 2055-2060.	2.2	32
59	Arrest all accessories—inhibition of hepatitis C virus by compounds that target host factors. <i>Discovery Medicine</i> , 2011, 12, 237-44.	0.5	32
60	Persistence of Occult Hepatitis B after Removal of the Hepatitis B Virus—Infected Liver. <i>Journal of Infectious Diseases</i> , 2008, 197, 355-360.	4.0	30
61	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. <i>Gastroenterology</i> , 2012, 143, 439-447.e1.	1.3	30
62	In vitro activity of itraconazole against SARS-CoV-2. <i>Journal of Medical Virology</i> , 2021, 93, 4454-4460.	5.0	30
63	RNA reference materials with defined viral RNA loads of SARS-CoV-2—A useful tool towards a better PCR assay harmonization. <i>PLoS ONE</i> , 2022, 17, e0262656.	2.5	29
64	Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 137-142.	1.4	29
65	Novel multiple swab method enables high efficiency in SARS-CoV-2 screenings without loss of sensitivity for screening of a complete population. <i>Transfusion</i> , 2020, 60, 2441-2447.	1.6	28
66	Second-wave Protease Inhibitors: Choosing an Heir. <i>Clinics in Liver Disease</i> , 2011, 15, 597-609.	2.1	27
67	Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication. <i>Frontiers in Microbiology</i> , 2021, 12, 701198.	3.5	27
68	Scavenger receptor class B member 1 ( SCARB1 ) variants modulate hepatitis C virus replication cycle and viral load. <i>Journal of Hepatology</i> , 2017, 67, 237-245.	3.7	26
69	Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure. <i>Frontiers in Immunology</i> , 2020, 11, 534731.	4.8	26
70	Hepatitis C virus core antigen testing in liver and kidney transplant recipients. <i>Journal of Viral Hepatitis</i> , 2014, 21, 769-779.	2.0	25
71	Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy. <i>Metabolites</i> , 2021, 11, 699.	2.9	25
72	Anti-HBc Seroconversion after Transplantation of Anti-HBc Positive Nonliver Organs to Anti-HBc Negative Recipients. <i>Transplantation</i> , 2006, 81, 808-809.	1.0	24

#	ARTICLE	IF	CITATIONS
73	Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. <i>Journal of Viral Hepatitis</i> , 2011, 18, 562-570.	2.0	24
74	Automated Nucleic Acid Isolation Methods for HDV viral Load Quantification can Lead to viral Load Underestimation. <i>Antiviral Therapy</i> , 2019, 24, 117-123.	1.0	24
75	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	2.9	24
76	Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP). <i>PLoS ONE</i> , 2015, 10, e0117152.	2.5	24
77	Comparative analysis of point-of-care, high-throughput and laboratory-developed SARS-CoV-2 nucleic acid amplification tests (NATs). <i>Journal of Virological Methods</i> , 2021, 291, 114102.	2.1	22
78	Role of BK polyomavirus (BKV) and Torque teno virus (TTV) in liver transplant recipients with renal impairment. <i>Journal of Medical Microbiology</i> , 2018, 67, 1496-1508.	1.8	22
79	SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment. <i>Cell Discovery</i> , 2022, 8, 42.	6.7	22
80	Impaired TRAIL-dependent cytotoxicity of CD1c-positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2008, 15, 200-211.	2.0	20
81	Membranous Budd-Chiari syndrome in Caucasians. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 226-234.	1.5	19
82	Clinical Outcome and Viral Genome Variability of Hepatitis B Virus-Induced Acute Liver Failure. <i>Hepatology</i> , 2019, 69, 993-1003.	7.3	19
83	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , 2021, 142, 104932.	3.1	19
84	Longitudinal Testing for Respiratory and Gastrointestinal Shedding of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Day Care Centers in Hesse, Germany. <i>Clinical Infectious Diseases</i> , 2021, 73, e3036-e3041.	5.8	18
85	Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2022, 40, 587-589.	16.8	18
86	Effects of cyclosporine on human dendritic cell subsets. <i>Transplantation Proceedings</i> , 2005, 37, 20-24.	0.6	17
87	Prevention strategies for blood-borne viruses in the Era of vaccines, direct acting antivirals and antiretroviral therapy. <i>Reviews in Medical Virology</i> , 2016, 26, 330-339.	8.3	17
88	Characterization of the inhibition of hepatitis C virus entry by <i>in vitro</i> -generated and patient-derived oxidized low-density lipoprotein. <i>Hepatology</i> , 2013, 57, 1716-1724.	7.3	16
89	Thirty years of CMV seroprevalence—a longitudinal analysis in a German university hospital. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1095-1102.	2.9	16
90	Landscape of T cell repertoires with public COVID-19-associated T cell receptors in pre-pandemic risk cohorts. <i>Clinical and Translational Immunology</i> , 2021, 10, e1340.	3.8	16

#	ARTICLE	IF	CITATIONS
91	Self-Collected Samples to Detect SARS-CoV-2: Direct Comparison of Saliva, Tongue Swab, Nasal Swab, Chewed Cotton Pads and Gargle Lavage. <i>Journal of Clinical Medicine</i> , 2021, 10, 5751.	2.4	16
92	Omicron variant of SARS-CoV-2 exhibits an increased resilience to the antiviral type I interferon response. , 2022, 1, .		16
93	Yellow Fever: Integrating Current Knowledge with Technological Innovations to Identify Strategies for Controlling a Re-Emerging Virus. <i>Viruses</i> , 2019, 11, 960.	3.3	15
94	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. <i>Microorganisms</i> , 2021, 9, 748.	3.6	14
95	Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response. <i>Vaccines</i> , 2022, 10, 585.	4.4	14
96	Cyclophilin polymorphism and virus infection. <i>Current Opinion in Virology</i> , 2015, 14, 47-49.	5.4	13
97	Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. <i>Journal of Clinical Virology</i> , 2017, 93, 46-52.	3.1	13
98	Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1049.	4.1	13
99	Development and optimization of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: Evaluation of 5676 Phase 1 Passed Structures. <i>Journal of Medical Virology</i> , 2022, 94, 3101-3111.	5.0	13
100	Wastewater surveillance allows early detection of SARS-CoV-2 omicron in North Rhine-Westphalia, Germany. <i>Science of the Total Environment</i> , 2022, 846, 157375.	8.0	13
101	Impact of immune suppressive agents on the BK-Polyomavirus non coding control region. <i>Antiviral Research</i> , 2018, 159, 68-76.	4.1	12
102	Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort. <i>Pathogens</i> , 2020, 9, 137.	2.8	12
103	A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization. <i>Scientific Reports</i> , 2021, 11, 11049.	3.3	12
104	Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1132-1139.	0.7	12
105	Prolonged Survival of Hepatitis C Virus in the Anesthetic Propofol. <i>Clinical Infectious Diseases</i> , 2011, 53, 963-964.	5.8	11
106	Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. <i>International Journal of Infectious Diseases</i> , 2016, 42, 1-3.	3.3	11
107	Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission. <i>Journal of Infectious Diseases</i> , 2018, 218, 1711-1721.	4.0	10
108	Sofosbuvir Activates EGFR-Dependent Pathways in Hepatoma Cells with Implications for Liver-Related Pathological Processes. <i>Cells</i> , 2020, 9, 1003.	4.1	10

#	ARTICLE	IF	CITATIONS
109	Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 366.e1-366.e7.	1.2	10
110	A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. <i>Antiviral Research</i> , 2017, 141, 116-123.	4.1	9
111	SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. <i>Journal of Hepatology</i> , 2019, 70, 603-614.	3.7	9
112	Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour. <i>Bioinformatics</i> , 2021, 37, 2282-2288.	4.1	9
113	Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model. <i>Life</i> , 2021, 11, 810.	2.4	9
114	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1212-1225.	2.4	9
115	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. <i>PLoS ONE</i> , 2011, 6, e24142.	2.5	9
116	SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination. <i>European Journal of Immunology</i> , 2022, 52, 1194-1197.	2.9	9
117	Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 63-79.	3.0	8
118	Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization. <i>Antiviral Research</i> , 2014, 101, 37-44.	4.1	8
119	The detection of BKPyV genotypes II and IV after renal transplantation as a simple tool for risk assessment for PyVAN and transplant outcome already at early stages of BKPyV reactivation. <i>Journal of Clinical Virology</i> , 2019, 113, 14-19.	3.1	8
120	High-Frequency Self-Testing by Schoolteachers for Sars-Cov-2 Using a Rapid Antigen Test: Results of the Safe School Hesse study. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2021, 118, 252-253.	0.9	8
121	COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view. <i>Journal of Molecular Medicine</i> , 2022, 100, 463-470.	3.9	8
122	Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. <i>Hepatology</i> , 2014, 60, 508-520.	7.3	7
123	Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators. <i>Gut</i> , 2016, 65, 1015-1023.	12.1	7
124	Environmental Stability and Infectivity of Hepatitis C Virus (HCV) in Different Human Body Fluids. <i>Frontiers in Microbiology</i> , 2018, 9, 504.	3.5	7
125	Characterization of the Filovirus-Resistant Cell Line SH-SY5Y Reveals Redundant Role of Cell Surface Entry Factors. <i>Viruses</i> , 2019, 11, 275.	3.3	7
126	Powered air-purifying respirators used during the SARS-CoV-2 pandemic significantly reduce speech perception. <i>Journal of Occupational Medicine and Toxicology</i> , 2021, 16, 43.	2.2	7



#	ARTICLE	IF	CITATIONS
127	A Rare Cause of Nonalcoholic Fatty Liver Disease. <i>Annals of Internal Medicine</i> , 2006, 145, 154.	3.9	7
128	Low But Recoverable Markers of Humoral Immune Response to BNT162b2 in Elderly LTCF Residents Five to Seven Months After Two-Dose Vaccination. <i>Frontiers in Aging</i> , 2022, 3, .	2.6	7
129	The Suppressive Effect That Myriocin Has on Hepatitis C Virus RNA Replication Is Independent of Inhibition of Serine Palmitoyl Transferase. <i>Journal of Infectious Diseases</i> , 2008, 198, 1091-1093.	4.0	6
130	Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?. <i>Annals of Hepatology</i> , 2010, 9, 181-185.	1.5	6
131	HBV reactivation in allogeneic stem cell transplant recipients: Risk factors, outcome, and role of hepatitis B virus mutations. <i>Hepatology Communications</i> , 2017, 1, 1014-1023.	4.3	6
132	Cationic amphiphilic drugs enhance entry of lentiviral particles pseudotyped with rabies virus glycoprotein into non-neuronal cells. <i>Antiviral Research</i> , 2015, 124, 122-131.	4.1	5
133	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 285-294.e1.	4.5	5
134	Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure. <i>Viruses</i> , 2019, 11, 863.	3.3	5
135	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	2.5	5
136	Clinical patterns associated with the concurrent detection of anti-HBs and HBV DNA. <i>Journal of Medical Virology</i> , 2018, 90, 282-290.	5.0	4
137	COVID-19 among children seeking primary paediatric care with signs of an acute infection. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 3315-3321.	1.5	4
138	SARS-CoV-2 screening strategies for returning international travellers: Evaluation of a rapid antigen test approach. <i>International Journal of Infectious Diseases</i> , 2022, 118, 126-131.	3.3	4
139	Stability and transmission of hepatitis C virus in different anesthetic agents. <i>American Journal of Infection Control</i> , 2013, 41, 942-943.	2.3	3
140	Pediatrics and COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 197-208.	1.6	3
141	Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. <i>Antiviral Research</i> , 2012, 96, 51-58.	4.1	2
142	Typical symptoms of common otorhinolaryngological diseases may mask a SARS-CoV-2 infection. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3551-3558.	1.6	2
143	Anti-parietal cell autoantibodies (PCA) in primary biliary cirrhosis: a putative marker for recurrence after orthotopic liver transplantation?. <i>Annals of Hepatology</i> , 2010, 9, 181-5.	1.5	2
144	A Lymphotoxin-Driven Pathway to Hepatocellular Carcinoma. <i>Cancer Cell</i> , 2009, 16, 447.	16.8	1

#	ARTICLE	IF	CITATIONS
145	Infectivity and stability of hepatitis C virus in different perfusion solutions. <i>Transplant Infectious Disease</i> , 2019, 21, e13135.	1.7	1
146	Efficient inactivation of pseudotyped HIV-based lentiviral vectors and infectious HIV. <i>Journal of Virological Methods</i> , 2020, 276, 113768.	2.1	1
147	Expression Cloning of Host Factors Required for the HCV Replication Cycle. <i>Methods in Molecular Biology</i> , 2019, 1911, 169-182.	0.9	1
148	772 SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYCLOPHILIN A AND THEIR INFLUENCE ON HCV RNA REPLICATION IN VITRO. <i>Journal of Hepatology</i> , 2011, 54, S310-S311.	3.7	0
149	Relevance of Resistance Against Direct Acting Antiviral Agents in Hepatitis C Virus Infection – What Technology do we Really Need in Clinical Practice?. <i>Current Hepatitis Reports</i> , 2013, 12, 195-199.	0.3	0
150	A novel mid-scale screening assay to identify compounds with anti-HDV activity. <i>Journal of Hepatology</i> , 2017, 66, S258.	3.7	0
151	Sodium taurocholate cotransporting polypeptide variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B. <i>Journal of Hepatology</i> , 2018, 68, S781.	3.7	0
152	Expanding the donor pool-decontamination of HCV RNA positive kidneys with methylene blue. <i>Journal of Hepatology</i> , 2018, 68, S764-S765.	3.7	0
153	Mutations in HCV NS3 but no Sec14L2 variants alter HCV RNA replication of natural occurring viruses in cell culture. <i>Journal of Hepatology</i> , 2018, 68, S763-S764.	3.7	0
154	THU-049-Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2019, 70, e181-e182.	3.7	0
155	Toll-like receptor 7 and 8 agonists as potent inhibitors of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2020, 73, S845-S846.	3.7	0
156	Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells. <i>Journal of Hepatology</i> , 2020, 73, S503.	3.7	0
157	Call for a pan-European COVID-19 response must be comprehensive – Authors' reply. <i>Lancet, The</i> , 2021, 397, 1541.	13.7	0
158	Correction: A Rare Cause of Nonalcoholic Fatty Liver Disease. <i>Annals of Internal Medicine</i> , 2006, 145, 396.	3.9	0
159	Living Repository of Millions of T and B Cell Receptor Sequences from Patients with COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
160	Landscape of Public T Cell Receptors Associated with Recovery from COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0